Skip to main content
Journal ArticleOPEN ACCESS

Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient with Anti-Interferon-γAutoantibodies

Clinical Infectious Diseases (2021) 72(12) 2206-2208
DOI: 10.1093/cid/ciaa1086
35Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patients with autoantibodies to interferon-γ(IFN-γ) may develop severe nontuberculous mycobacterial infections. We describe the novel use of daratumumab in a patient with autoantibodies to IFN-γwho had progressive infection, resulting in clinical and radiographic improvement.

Author supplied keywords

Cite

CITATION STYLE

APA

Ochoa, S., DIng, L., Kreuzburg, S., Treat, J., Holland, S. M., & Zerbe, C. S. (2021). Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient with Anti-Interferon-γAutoantibodies. Clinical Infectious Diseases, 72(12), 2206–2208. https://doi.org/10.1093/cid/ciaa1086

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free